TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18419878

Group type: EXPERIMENTAL
Intervention: budesonide DPI-B 360 microg twice-daily (total daily dose 720 microg)
Number of subjects: 1137

Group type: EXPERIMENTAL
Intervention: budesonide DPI-A 400 microg twice-daily (total daily dose 800 microg)
Number of subjects: 1137

Group type: EXPERIMENTAL
Intervention: budesonide DPI-B 180 microg once daily (total daily dose 180 microg)
Number of subjects: 1137

Group type: EXPERIMENTAL
Intervention: budesonide DPI-A 200 microg once daily (total daily dose 200 microg)
Number of subjects: 1137

Group type: EXPERIMENTAL
Intervention: budesonide DPI-B 360 microg twice-daily
Number of subjects: 1137

Group type: EXPERIMENTAL
Intervention: budesonide DPI-A 400 microg twice-daily
Number of subjects: 1137

Group type: EXPERIMENTAL
Intervention: budesonide DPI-B 180 microg once daily
Number of subjects: 1137

Group type: EXPERIMENTAL
Intervention: budesonide DPI-A 200 microg once daily
Number of subjects: 1137

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1137
Study: 16965691

Group type: EXPERIMENTAL
Intervention: Parenteral nutrition with alanyl-glutamine dipeptide
Number of subjects: 72
Study: 12856155

Group type: EXPERIMENTAL
Intervention: 0.9 mg recombinant human TSH (rhTSH) followed by 2 mCi (74 MBq) iodine-131
Number of subjects: 9

Group type: COMPARATOR
Intervention: 2 mCi (74 MBq) iodine-131 administered after stopping thyroid hormones to become hypothyroid
Number of subjects: 9
Study: 11028139

Group type: EXPERIMENTAL
Intervention: Home rehabilitation
Number of subjects: 1487
Study: 9368461

Group type: EXPERIMENTAL
Intervention: Mentored teens
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control teens
Number of subjects: 110
Study: 1328365

Group type: EXPERIMENTAL
Intervention: Dietary treatment based upon weight reduction and sodium restriction
Number of subjects: 64

Group type: COMPARATOR
Intervention: Drug treatment using a stepped-care approach with atenolol as first choice drug
Number of subjects: 64
Study: 3870293

Group type: EXPERIMENTAL
Intervention: Aclatonium napadisilate (TM-723) at a dose of 50 mg
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Prostaglandine F2 alpha (PGF2 alpha) at a dose of 2 mg
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 30291013

Group type: EXPERIMENTAL
Intervention: Albiglutide (30-50 mg, subcutaneous injection once a week)
Number of subjects: 9463

Group type: COMPARATOR
Intervention: Placebo (matched volume, subcutaneous injection once a week)
Number of subjects: 9463

Group type: EXPERIMENTAL
Intervention: Albiglutide
Number of subjects: 9463

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9463
Study: 27692424

Group type: EXPERIMENTAL
Intervention: Augmented corticotomy (experimental group, n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (without augmented corticotomy, n = 15)
Number of subjects: 30
Study: 24607553

Group type: EXPERIMENTAL
Intervention: etanercept (0.4 mg/kg twice weekly × 4 weeks)
Number of subjects: 34

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: etanercept
Number of subjects: 34
Study: 23192918

Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated IN.PACT Pacific balloons
Number of subjects: 85
Study: 20206356

Group type: EXPERIMENTAL
Intervention: Oral prednisone for 40 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (non-treated patients)
Number of subjects: 40
Study: 18380933

Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Tamsulosin plus Levofloxacin
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 105
Study: 18596318

Group type: EXPERIMENTAL
Intervention: Olive oil (OO) based lipid emulsion
Number of subjects: 38

Group type: COMPARATOR
Intervention: Soybean oil (SO) based lipid emulsion
Number of subjects: 38
Study: 15028067

Group type: EXPERIMENTAL
Intervention: Nonsustained ventricular tachycardia (NSVT)
Number of subjects: 923

Group type: COMPARATOR
Intervention: No nonsustained ventricular tachycardia (NSVT)
Number of subjects: 923

Group type: EXPERIMENTAL
Intervention: NSVT index peaks < or =3 days prior to sustained VT/VF
Number of subjects: 923

Group type: EXPERIMENTAL
Intervention: NSVT index peaks >3 days prior to sustained VT/VF
Number of subjects: 923
Study: 11735351

Group type: EXPERIMENTAL
Intervention: Astemizole
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 27
Study: 9431859

Group type: EXPERIMENTAL
Intervention: 75 mg irbesartan once a day
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: 150 mg irbesartan once a day
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: 75 mg irbesartan twice a day
Number of subjects: 215

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study: 8237833

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 228

Group type: COMPARATOR
Intervention: Conventional antiarrhythmic therapy
Number of subjects: 228
Study: 3800090

Group type: EXPERIMENTAL
Intervention: Topical 1% povidone-iodine (Betadine)
Number of subjects: 395

Group type: COMPARATOR
Intervention: Control group (normal saline without scrubbing)
Number of subjects: 395
Study: 30371101

Group type: EXPERIMENTAL
Intervention: Modeling-based narrative intervention
Number of subjects: 67

Group type: COMPARATOR
Intervention: Didactic education (Control)
Number of subjects: 67
Study: 29916140

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg daily
Number of subjects: 11015

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11015

Group type: EXPERIMENTAL
Intervention: Pravastatin (PROSPER trial)
Number of subjects: 11015

Group type: EXPERIMENTAL
Intervention: Pravastatin (WOSCOPS trial)
Number of subjects: 11015
Study: 27577515

Group type: EXPERIMENTAL
Intervention: 80 kVp tube voltage, low-concentration contrast media, iterative reconstruction (Group B)
Number of subjects: 154

Group type: COMPARATOR
Intervention: 120 kVp tube voltage, high-concentration contrast media, filtered back projection reconstruction (Group A)
Number of subjects: 154
Study: 25277022

Group type: EXPERIMENTAL
Intervention: Cued (lower workload)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Uncued (higher workload)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Lower-frequency alpha (8 to 10.9 Hz)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Task Load Index (TLI)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Frontal theta and Engagement Index (El)
Number of subjects: 92
Study: 22134839

Group type: EXPERIMENTAL
Intervention: Colesevelam (3.75 g/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 20638059

Group type: EXPERIMENTAL
Intervention: Letrozole (aromatase inhibitor)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 17999256

Group type: EXPERIMENTAL
Intervention: Atypical antipsychotic drugs (various types)
Number of subjects: 1460

Group type: COMPARATOR
Intervention: Psychiatrists' management practices
Number of subjects: 1460
Study: 16330296

Group type: EXPERIMENTAL
Intervention: Macrozit (test formulation)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Azitrocin (reference formulation)
Number of subjects: 28
Study: 12480477

Group type: EXPERIMENTAL
Intervention: Early learning phase using simple categorization rules
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Later learning phase using similarity-based exemplar retrieval
Number of subjects: 0
Study: 9472885

Group type: EXPERIMENTAL
Intervention: rtPA
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8600739

Group type: EXPERIMENTAL
Intervention: Ipsilateral graft harvest
Number of subjects: 65

Group type: COMPARATOR
Intervention: Contralateral graft harvest
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Graft harvest in knees with ACL reconstruction
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Donor site morbidity
Number of subjects: 65
Study: 2573234

Group type: EXPERIMENTAL
Intervention: Carbamazepine plus neuroleptics (n = 82)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo plus neuroleptics (n = 80)
Number of subjects: 162
Study: 4853932

Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy with pyloroplasty (PGVP)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Proximal gastric vagotomy (PGV)
Number of subjects: 78
Study: 31571445

Group type: EXPERIMENTAL
Intervention: Teneligliptin 20 mg once daily for 12 weeks
Number of subjects: 76

Group type: COMPARATOR
Intervention: Sitagliptin 100 mg once daily for 12 weeks
Number of subjects: 76
Study: 28255099

Group type: EXPERIMENTAL
Intervention: NT‐proBNP levels in individuals with newly detected AF (n=96)
Number of subjects: 7173

Group type: COMPARATOR
Intervention: NT‐proBNP levels in individuals without AF (n=742)
Number of subjects: 7173

Group type: EXPERIMENTAL
Intervention: NT‐proBNP cut-off of ≥125 ng/L
Number of subjects: 7173
Study: 26340887

Group type: EXPERIMENTAL
Intervention: Tongue strengthening exercises at 60% of maximal tongue strength
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Tongue strengthening exercises at 80% of maximal tongue strength
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Tongue strengthening exercises at 100% of maximal tongue strength
Number of subjects: 51
Study: 21709132

Group type: EXPERIMENTAL
Intervention: Health care providers' written prescriptions for physical activity with additional physical activity resources
Number of subjects: 0

Group type: COMPARATOR
Intervention: Health care providers' written prescriptions for physical activity without additional physical activity resources
Number of subjects: 0
Study: 21420278

Group type: EXPERIMENTAL
Intervention: Custom-made splint
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Prefabricated splint
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both splints
Number of subjects: 56
Study: 19454185

Group type: EXPERIMENTAL
Intervention: Graves' disease (hyperthyroidism)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Hashimoto's thyroiditis (subclinical hypothyroidism)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Nodular goiter (control)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Hashimoto's thyroiditis (euthyroid)
Number of subjects: 78
Study: 17826373

Group type: EXPERIMENTAL
Intervention: Fibrinolysis
Number of subjects: 958

Group type: COMPARATOR
Intervention: Primary Percutaneous Coronary Intervention (PCI)
Number of subjects: 958
Study: 15063430

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 2027

Group type: EXPERIMENTAL
Intervention: Calcium channel blockers
Number of subjects: 2027

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 2027

Group type: EXPERIMENTAL
Intervention: First drug or combination
Number of subjects: 2027
Study: 14962527

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 434

Group type: COMPARATOR
Intervention: Best treatment without hormones (non-HRT)
Number of subjects: 434
Study: 11174240

Group type: EXPERIMENTAL
Intervention: Intravenous tissue plasminogen activator (tPA)
Number of subjects: 0
Study: 9247941

Group type: EXPERIMENTAL
Intervention: Midazolam with fentanyl
Number of subjects: 0

Group type: COMPARATOR
Intervention: Midazolam without fentanyl
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midazolam (general)
Number of subjects: 0
Study: 8391063

Group type: EXPERIMENTAL
Intervention: High-dose vitamin A (retinol palmitate, orally 300,000 IU daily for 12 months)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: High-dose vitamin A
Number of subjects: 307

Group type: COMPARATOR
Intervention: Control
Number of subjects: 307
Study: 2881481

Group type: EXPERIMENTAL
Intervention: Esmolol (300 micrograms/kg/min)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nitroprusside (10 micrograms/kg/min)
Number of subjects: 20
Study: 31994479

Group type: EXPERIMENTAL
Intervention: 2016 ACR-EULAR criteria
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: AECG criteria
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: ACR criteria
Number of subjects: 350
Study: 28862483

Group type: EXPERIMENTAL
Intervention: Peer change agent intervention (PrEP/peer change agent training workshop followed by booster calls for 12 months)
Number of subjects: 423

Group type: COMPARATOR
Intervention: Minimal contact attention control (sex diary activity)
Number of subjects: 423
Study: 27511742

Group type: EXPERIMENTAL
Intervention: Ganoderma lucidum (3 g/day for 16 weeks)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Ganoderma lucidum with Cordyceps sinensis (3 g/day for 16 weeks)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 23629946

Group type: EXPERIMENTAL
Intervention: exercise pause
Number of subjects: 12

Group type: COMPARATOR
Intervention: relaxation pause
Number of subjects: 12

Group type: COMPARATOR
Intervention: without pause
Number of subjects: 12
Study: 23636087

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided caudal epidural steroid injection
Number of subjects: 120

Group type: COMPARATOR
Intervention: Fluoroscopy-guided caudal epidural steroid injection
Number of subjects: 120
Study: 19924670

Group type: EXPERIMENTAL
Intervention: 1 mg/kg oral prednisolone for 10 days
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 19138994

Group type: EXPERIMENTAL
Intervention: Chromoendoscopy
Number of subjects: 54

Group type: COMPARATOR
Intervention: Intensive inspection
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard colonoscopy
Number of subjects: 54
Study: 16380544

Group type: EXPERIMENTAL
Intervention: 1.6 mg/d riboflavin for 12 weeks
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 35
Study: 14964680

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine applied before or after acid etching
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control groups with no chlorhexidine application
Number of subjects: 24
Study: 10379275

Group type: EXPERIMENTAL
Intervention: Pulsed Nd:YAG laser (1 W, 15 pps, 1 s)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no laser treatment)
Number of subjects: 38
Study: 8882239

Group type: EXPERIMENTAL
Intervention: McCoy laryngoscope (size 3) in standard Macintosh configuration followed by activation of the distal hinged tip
Number of subjects: 102
Study: 1354225

Group type: EXPERIMENTAL
Intervention: Cetirizine, 15 mg twice a day (6 patients)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (6 patients)
Number of subjects: 12
Study: 6238133

Group type: EXPERIMENTAL
Intervention: DDAVP (vasopressin derivative) administered for 10 days, 40 micrograms per day
Number of subjects: 9
Study: 31046500

Group type: EXPERIMENTAL
Intervention: Testing every 2 months until 12 months (Groups 2, 3, and 4)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Feedback-enhanced testing at 6 months (Group 3)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Feedback-enhanced testing at 2, 6, and 10 months (Group 4)
Number of subjects: 106

Group type: COMPARATOR
Intervention: No testing until 12 months (Group 1)
Number of subjects: 106
Study: 27864620

Group type: EXPERIMENTAL
Intervention: Inside-out or Outside-in TO-TVT
Number of subjects: 46
Study: 26453645

Group type: EXPERIMENTAL
Intervention: EBV IgG antibody levels
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Cotinine levels
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Highest quintile of EBNA-1 IgG levels
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Cotinine levels >25 ng/mL
Number of subjects: 468
Study: 23350967

Group type: EXPERIMENTAL
Intervention: Ventricular tachycardia (VT) ablation
Number of subjects: 95

Group type: COMPARATOR
Intervention: ICD only treatment
Number of subjects: 95
Study: 21263058

Group type: EXPERIMENTAL
Intervention: Lidocaine 2% (1 mg/kg)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: IV Fentanyl (1 μg/kg)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Lidocaine 2% (1 mg/kg) and IV Fentanyl (1 μg/kg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 19136368

Group type: EXPERIMENTAL
Intervention: Nurse-led care (model A) using home autoadjusting positive airway pressure to set therapeutic CPAP, supervised by an experienced nurse.
Number of subjects: 619

Group type: COMPARATOR
Intervention: Physician-led care (model B) involving two laboratory polysomnograms to diagnose and treat OSA, supervised by a sleep physician.
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Nurse-led care (model A)
Number of subjects: 619

Group type: COMPARATOR
Intervention: Physician-led care (model B)
Number of subjects: 619
Study: 17211873

Group type: COMPARATOR
Intervention: Psychological Screening Inventory (PSI)
Number of subjects: 0
Study: 15115576

Group type: EXPERIMENTAL
Intervention: Case-group (high climate temperature, n=6)
Number of subjects: 6

Group type: COMPARATOR
Intervention: I Control-group (n=10)
Number of subjects: 6

Group type: COMPARATOR
Intervention: II Control-group (n=9)
Number of subjects: 6
Study: 11895966

Group type: EXPERIMENTAL
Intervention: WRSS1 vaccine (3 x 10(3) CFU)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: WRSS1 vaccine (3 x 10(4) CFU)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: WRSS1 vaccine (3 x 10(5) CFU)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: WRSS1 vaccine (3 x 10(6) CFU)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: WRSS1 vaccine (all groups)
Number of subjects: 34
Study: 9455517

Group type: EXPERIMENTAL
Intervention: Oral azithromycin prophylaxis (500 mg/week)
Number of subjects: 1016

Group type: COMPARATOR
Intervention: Benzathine penicillin G (BPG)
Number of subjects: 1016

Group type: COMPARATOR
Intervention: No-treatment group
Number of subjects: 1016
Study: 7872318

Group type: EXPERIMENTAL
Intervention: Increased dialysis prescriptions
Number of subjects: 59

Group type: COMPARATOR
Intervention: Standard dialysis prescriptions (no change)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Higher dialysis efficacy (Kt/V urea and nPCR of 1.28 and 1.22 g/kg/d)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Lower dialysis efficacy (Kt/V urea and nPCR of 1.09 and 1.01)
Number of subjects: 59
Study: 2205161

Group type: EXPERIMENTAL
Intervention: Bubble oxygenator (Cobe)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Bubble oxygenator (Polystan)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Membrane oxygenator (SciMed)
Number of subjects: 33
Study: 645142

Group type: EXPERIMENTAL
Intervention: 5 mg glibenclamide daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual diet therapy
Number of subjects: 0
Study: 7170283

Group type: EXPERIMENTAL
Intervention: Unsuckled breasts (intervention)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Suckled breasts (control)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Diurnal feeds (unsuckled)
Number of subjects: 10
Study: 31179531

Group type: EXPERIMENTAL
Intervention: Artisanal medical CBD oil (2-5 mg/kg/day, up-titrated to a maximum of 25 mg/kg/day) added to baseline AED regimen for at least 6 months.
Number of subjects: 29
Study: 29578103

Group type: EXPERIMENTAL
Intervention: Bronchodilator (BD; ipratropium 0.5mg + salbutamol 2.5 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (PL; normal saline)
Number of subjects: 20
Study: 26514352

Group type: EXPERIMENTAL
Intervention: Oral anticoagulation with dabigatran after pulmonary vein isolation for atrial fibrillation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 25068546

Group type: EXPERIMENTAL
Intervention: Trichloroacetic acid (TCA) peeling 25%
Number of subjects: 65

Group type: COMPARATOR
Intervention: Q-switched Nd:YAG laser
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Epidermal type of melasma
Number of subjects: 65
Study: 22799893

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard cessation intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard intervention plus components to address weight concerns
Number of subjects: 0
Study: 20601671

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) 50 IU/kg/week
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (no EPO treatment)
Number of subjects: 33
Study: 17599427

Group type: EXPERIMENTAL
Intervention: Recruitment strategies used in the vanguard phase (chart and database review)
Number of subjects: 10251

Group type: EXPERIMENTAL
Intervention: Recruitment strategies used in the main trial
Number of subjects: 10251

Group type: EXPERIMENTAL
Intervention: Immediate start of enrollment by clinics at the beginning of the main trial
Number of subjects: 10251
Study: 15109699

Group type: EXPERIMENTAL
Intervention: Lag-click condition
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Single-click condition
Number of subjects: 91

Group type: COMPARATOR
Intervention: Intensity levels (43, 58, or 73 dB)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Gender
Number of subjects: 91
Study: 11401877

Group type: EXPERIMENTAL
Intervention: Glycophosphopeptical (Inmunoferón) at oral doses of 3 g/d for 90 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 9184521

Group type: EXPERIMENTAL
Intervention: Injection drug use history among homeless men in Baltimore
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Injection drug use history among homeless men in Boston
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Injection drug use history among homeless women in Baltimore
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Injection drug use history among homeless women in Boston
Number of subjects: 368
Study: 8278664

Group type: EXPERIMENTAL
Intervention: Ideokinetic imagery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Flexibility combined with abdominal strength training
Number of subjects: 0
Study: 3448513

Group type: EXPERIMENTAL
Intervention: Gd-DTPA (intravenous contrast medium for MRI)
Number of subjects: 50

Group type: COMPARATOR
Intervention: CT scanning without Gd-DTPA
Number of subjects: 50

Group type: COMPARATOR
Intervention: MR scanning without Gd-DTPA
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: MR scanning with Gd-DTPA
Number of subjects: 50
Study: 29092879

Group type: EXPERIMENTAL
Intervention: 1 egg/day for 6 months (n = 80)
Number of subjects: 163

Group type: COMPARATOR
Intervention: No intervention (control group; n = 83)
Number of subjects: 163